This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| C-reactive protein | |
|---|---|
| Name | C-reactive protein |
| Organism | Human |
| Uniprot | P02741 |
| Gene | CRP |
C-reactive protein C-reactive protein is an acute-phase plasma protein produced primarily by the liver that rises rapidly in response to inflammation. Discovered during studies of pneumonia in the early 20th century, it has become a widely used clinical biomarker in Cardiology, Rheumatology, and infectious disease practice. CRP links innate immune recognition to effector systems and is studied across fields including Immunology, Molecular Biology, Epidemiology, and Pharmacology.
CRP is a pentameric protein composed of five identical subunits arranged symmetrically, forming a disc-shaped molecule with a central pore. Each subunit of CRP contains a calcium-dependent ligand-binding site that recognizes phosphocholine and other phosphorylated ligands, a property shared with members of the Pentraxins family such as Serum amyloid P component. The human CRP polypeptide is encoded by the CRP gene located on chromosome 1 and is synthesized as a 206 amino-acid precursor with post-translational modifications typical of secreted hepatic proteins. High-resolution structures obtained by X-ray crystallography and cryo-electron microscopy have been compared alongside structural studies of proteins like Hemoglobin and Immunoglobulin G to elucidate ligand interactions and conformational changes that can produce monomeric CRP forms implicated in tissue activity.
CRP is an effector of the innate immune system that opsonizes pathogens and damaged cells for clearance. It activates the classical complement pathway via C1q binding, analogous to antibody-mediated complement activation observed with Immunoglobulin M and Immunoglobulin G, and interacts with Fc gamma receptors on phagocytes similar to mechanisms described for Fc receptor (FcR). Hepatic CRP synthesis is under transcriptional control by cytokines such as Interleukin-6 and Interleukin-1β, with regulatory input from the Janus kinase/Signal transducer and activator of transcription (JAK/STAT) signaling axis and factors like C/EBPβ. Extrahepatic expression has been reported in cell types studied in research on Endothelial cells, Macrophages, and Adipocytes, paralleling findings in inflammatory studies of Type 2 diabetes mellitus and Obesity.
CRP is widely used as a clinical biomarker for acute inflammation, infection, and risk stratification in chronic conditions. In Cardiovascular disease research and trials, CRP levels have been evaluated alongside other prognostic markers such as Low-density lipoprotein measurements and imaging modalities like Coronary angiography. High-sensitivity CRP assays are employed in population epidemiology studies including cohorts from Framingham Heart Study, Nurses' Health Study, and INTERHEART to estimate cardiovascular risk. In Infectious disease practice, serial CRP measurements guide antimicrobial stewardship and treatment decisions in settings comparable to diagnostic strategies used in Sepsis and Community-acquired pneumonia. CRP has been integrated into clinical guidelines in specialties such as Rheumatology for monitoring disease activity in conditions like Rheumatoid arthritis and in perioperative care pathways developed in surgical centers including Mayo Clinic and Cleveland Clinic.
CRP concentration is determined by immunoassays that span standard clinical ranges to high-sensitivity formats for cardiovascular risk assessment. Assay technologies include nephelometry, turbidimetry, enzyme-linked immunosorbent assays comparable to methods used for Troponin I and B-type natriuretic peptide, and point-of-care lateral flow tests employed in emergency departments and primary care clinics associated with institutions such as Johns Hopkins Hospital and Guy's and St Thomas' NHS Foundation Trust. Interpretation requires context: markedly elevated CRP values are typical of acute bacterial infection or major tissue injury, whereas low-grade elevations are used in chronic risk models like those applied in American Heart Association and European Society of Cardiology guidance. Pre-analytical variables and biological confounders, such as age, smoking history, and concurrent medications studied in trials by groups including The Cochrane Collaboration, influence test performance and clinical thresholds.
Beyond being a marker, CRP may participate in pathogenesis through complement activation, modulation of phagocyte function, and alteration of endothelial behavior. Experimental work has implicated CRP in atherosclerotic plaque inflammation alongside findings from studies on Plaque rupture and mechanisms studied in Statin trials. Animal models and ex vivo experiments examining interactions with pathways involving Toll-like receptor 4, NOD-like receptors, and oxidative stress enzymes provide converging evidence for context-dependent pro-inflammatory or protective roles. Research on CRP intersects with investigations into Alzheimer's disease, Inflammatory bowel disease, and post-surgical complications, mirroring multidisciplinary studies conducted at centers like Massachusetts General Hospital and Karolinska Institutet.
Therapeutic approaches aim either to lower CRP levels indirectly by targeting upstream cytokines, as seen with anti-Interleukin-6 receptor therapies used in Rheumatology and Oncology trials, or to modulate CRP activity directly using small molecules, antisense oligonucleotides, and extracorporeal removal techniques evaluated in experimental studies. Large-scale randomized trials such as those inspired by cardiovascular outcome studies involving Canakinumab have informed whether CRP lowering translates to clinical benefit, and drug development strategies reference regulatory frameworks from agencies like the Food and Drug Administration and European Medicines Agency. Lifestyle interventions promoted by public health programs from organizations like the World Health Organization and national agencies also reduce baseline CRP through effects on risk factors like adiposity and smoking.
Category:Human proteins